Online citations, reference lists, and bibliographies.
← Back to Search

α-Galactosidase Delivery Using 30Kc19-human Serum Albumin Nanoparticles For Effective Treatment Of Fabry Disease

Hong Jai Lee, Hee Ho Park, Youngsoo Sohn, Jina Ryu, J. Park, W. J. Rhee, T. Park
Published 2016 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Fabry disease is a genetic lysosomal storage disease caused by deficiency of α-galactosidase, the enzyme-degrading neutral glycosphingolipid that is transported to lysosome. Glycosphingolipid accumulation by this disease causes multi-organ dysfunction and premature death of the patient. Currently, enzyme replacement therapy (ERT) using recombinant α-galactosidase is the only treatment available for Fabry disease. To maximize the efficacy of treatment, enhancement of cellular delivery and enzyme stability is a challenge in ERT using α-galactosidase. In this study, protein nanoparticles using human serum albumin (HSA) and 30Kc19 protein, originating from silkworm, were used to enhance the delivery and intracellular α-galactosidase stability. 30Kc19-HSA nanoparticles loaded with the α-galactosidase were formed by desolvation method. 30Kc19-HSA nanoparticles had a uniform spherical shape and were well dispersed in cell culture media. 30Kc19-HSA nanoparticles had negligible toxicity to human cells. The nanoparticles exhibited enhanced cellular uptake and intracellular stability of delivered α-galactosidase in human foreskin fibroblast. Additionally, they showed enhanced globotriaosylceramide degradation in Fabry patients’ fibroblasts. It is expected that 30Kc19-HSA protein nanoparticles could be used as an effective tool for efficient delivery and enhanced stability of drugs.
This paper references
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.
G. Linthorst (2004)
Inhibition of apoptosis by recombinant 30K protein originating from silkworm hemolymph.
E. H. Kim (2003)
Biofunctionalized targeted nanoparticles for therapeutic applications.
A. Wang (2008)
Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells.
S. Azarmi (2006)
Anti-apoptosis engineering
Eun Jeong Kim (2003)
Enhancement of recombinant protein production in Chinese hamster ovary cells through anti‐apoptosis engineering using 30Kc6 gene
S. Choi (2006)
Silkworm hemolymph inhibits baculovirus-induced insect cell apoptosis.
W. J. Rhee (2000)
Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs.
J. M. Irache (2005)
A protein delivery system using 30Kc19 cell-penetrating protein originating from silkworm.
J. Park (2012)
The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001
R. C. Scriver (2001)
Identification and characterization of a novel cell-penetrating peptide of 30Kc19 protein derived from Bombyx mori
Hee Ho Park (2014)
Enhancement of recombinant human EPO production and sialylation in chinese hamster ovary cells through Bombyx mori 30Kc19 gene expression
Zesong Wang (2011)
Nano and microparticles as controlled drug delivery devices.
M. N. R. Ravi Kumar (2000)
Beneficial effect of silkworm hemolymph on a CHO cell system: Inhibition of apoptosis and increase of EPO production.
S. Choi (2005)
Enhancement of human erythropoietin production in Chinese hamster ovary cells through supplementation of 30Kc19-30Kc6 fusion protein
Hee Ho Park (2015)
Kinetic Effect of Silkworm Hemolymph on the Delayed Host Cell Death in an Insect Cell‐Baculovirus System
Won Jong Rhee (1999)
Crystal structure of the 30 K protein from the silkworm Bombyx mori reveals a new member of the β-trefoil superfamily.
Jie-Pin Yang (2011)
Inhibition of Apoptosis by a Bombyx mori Gene
E. H. Kim (2004)
Efficient production of recombinant protein in Spodoptera frugiperda/AcNPV system utilizing silkworm hemolymph
S. Ha (2004)
TH (2012a) A protein delivery system using 30Kc19 cell-penetrating protein originating from silkworm. Biomaterials
JH Park (2012)
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.
K. Lee (2003)
Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
A. Vedder (2007)
Albumin-based nanoparticles as potential controlled release drug delivery systems.
Ahmed O Elzoghby (2012)
Silkworm hemolymph as a substitute for fetal bovine serum in insect cell culture
S. Ha (1996)
Silkworm hemolymph as a potent inhibitor of apoptosis in Sf9 cells.
W. J. Rhee (2002)
Desolvation process and surface characterisation of protein nanoparticles.
C. Weber (2000)
Albumin nanoparticles with predictable size by desolvation procedure
B. von Storp (2012)
Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles.
Hong Jai Lee (2014)
Inhibition of Human Cell Apoptosis by Silkworm Hemolymph
S. Choi (2002)
Stabilization of enzymes by the recombinant 30Kc19 protein
J. Park (2012)
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.
Anja Zensi (2009)

This paper is referenced by
Enzyme delivery using protein-stabilizing and cell-penetrating 30Kc19α protein nanoparticles
Hee Ho Park (2017)
Synthesis and biological evaluation of new water-soluble photoactive chlorin conjugate for targeted delivery.
Vasilii F. Otvagin (2018)
Protein-based direct reprogramming of fibroblasts to neuronal cells using 30Kc19 protein and transcription factor Ascl1.
Jina Ryu (2020)
CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges
M. Edelmann (2020)
Silkworm storage protein Bm30K-19G1 has a certain antifungal effects on Beauveria bassiana.
Ruilin Li (2019)
Protein-Based Nanoparticles as Drug Delivery Systems
Seyoung Hong (2020)
Allocolchicinoids bearing a Michael acceptor fragment for possible irreversible binding of tubulin
Ekaterina S. Sazanova (2020)
Nanocomposites as biomolecules delivery agents in nanomedicine
M. Bamburowicz-Klimkowska (2019)
Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives
M. Solomon (2017)
New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
M. R. Gigliobianco (2019)
Investigation of Vesicular-Mediated Transport of Intercellular Adhesion Molecule-1-Targeted Carriers for Treatment of Lysosomal Storage Disorders
R. L. Manthe (2017)
Semantic Scholar Logo Some data provided by SemanticScholar